Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism

Translational Psychiatry

Volumn 8, Issue 1, 2018, Pages

  Rose, Shannon ^a   Bennuri, Sirish C ^a   Davis, Jakeira E ^a   Wynne, Rebecca ^a   Slattery, John C ^a   Tippett, Marie ^a   Delhey, Leanna ^a   Melnyk, Stephan ^a   Kahler, Stephen G ^a   MacFabe, Derrick F ^b   Frye, Richard E ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ALBERTA CHILDREN S HOSPITAL RESEARCH INSTITUTE   (Canada)

^c PHOENIX CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUTYRIC ACID; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; UNCOUPLING PROTEIN 2; BUTYRIC ACID DERIVATIVE;

ADOLESCENT; ARTICLE; AUTISM; BEHAVIOR; CELL ACTIVITY; CELL FUNCTION; CHILD; CONTROLLED STUDY; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; LEARNING; LYMPHOBLASTOID CELL LINE; MALE; MEMORY; MICROBIOME; MITOCHONDRIAL GENE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; CELL LINE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; INTESTINE FLORA; LYMPHOCYTE; METABOLISM;

AUTISM SPECTRUM DISORDER; BUTYRATES; CELL LINE; CHILD; GASTROINTESTINAL MICROBIOME; HUMANS; LYMPHOCYTES; MALE; MITOCHONDRIA; MITOCHONDRIAL DISEASES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 85041620767     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/s41398-017-0089-z     Document Type: Article

References (111)

1. Rosenfeld, C. S. Microbiome disturbances and autism spectrum disorders. Drug. Metab. Dispos. 43, 1557-1571 (2015).
2. Frye, R. E. et al. Approaches to studying and manipulating the enteric microbiome to improve autism symptoms. Microb. Ecol. Health Dis. 26, 26878 (2015).
3. Turnbaugh, P. J. & Gordon, J. I. The core gut microbiome, energy balance and obesity. J. Physiol. 587, 4153-4158 (2009).
4. Naviaux, R. K. Metabolic features of the cell danger response. Mitochondrion 16, 7-17 (2014).
5. Johnson, C. C. & Ownby, D. R. Allergies and asthma: do atopic disorders result from inadequate immune homeostasis arising from infant gut dysbiosis? Expert. Rev. Clin. Immunol. 12, 379-388 (2016).
6. Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. Science 336, 1262-1267 (2012).
7. Mackenzie, A. E. & Milligan, G. The emerging pharmacology and function of GPR35 in the nervous system. Neuropharmacology 113, 661-671 (2017).
8. Cureau, N., AlJahdali, N., Vo, N. & Carbonero, F. Epigenetic mechanisms in microbial members of the human microbiota: current knowledge and perspectives. Epigenomics 8, 1259-1273 (2016).
9. Woo, V. & Alenghat, T. Host-microbiota interactions: epigenomic regulation. Curr. Opin. Immunol. 44, 52-60 (2017).
10. Borre, Y. E., Moloney, R. D., Clarke, G., Dinan, T. G. & Cryan, J. F. The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. Adv. Exp. Med. Biol. 817, 373-403 (2014).
11. Bull, M. J. & Plummer, N. T. Part 2: Treatments for chronic gastrointestinal disease and gut dysbiosis. Integr. Med. 14, 25-33 (2015).
12. Gollwitzer, E. S. & Marsland, B. J. Microbiota abnormalities in inflammatory airway diseases - potential for therapy. Pharmacol. Ther. 141, 32-39 (2014).
13. Palacios, T. et al. The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized controlled trial. Trials 18, 7 (2017).
14. Paun, A., Yau, C. & Danska, J. S. The influence of the microbiome on type 1 diabetes. J. Immunol. 198, 590-595 (2017).
15. Wegielska, I. & Suliburska, J. The role of intestinal microbiota in the pathogenesis of metabolic diseases. Acta Sci. Pol. Technol. Aliment. 15, 201-211 (2016).
16. Bischoff, S. C. et al. Towards a multidisciplinary approach to understand and manage obesity and related diseases. Clin. Nutr. 36, 917-938 (2017).
17. Fandriks, L. Roles of the gut in the metabolic syndrome: an overview. J. Intern. Med. 281, 319-336 (2017).
18. Bourassa, M.W., Alim, I., Bultman, S. J. & Ratan, R. R. Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? Neurosci. Lett. 625, 56-63 (2016).
19. Diaz Heijtz, R. et al. Normal gut microbiota modulates brain development and behavior. Proc. Natl. Acad. Sci. USA 108, 3047-3052 (2011).
20. Slattery, J., MacFabe, D. F. & Frye, R. E. The significance of the enteric microbiome on the development of childhood disease: a review of prebiotic and probiotic therapies in disorders of childhood. Clin. Med. Insights Pediatr. 10, 91-107 (2016).
21. Slattery, J., MacFabe, D. F., Kahler, S. G. & Frye, R. E. Enteric ecosystem disruption in autism spectrum disorder: can the microbiota and macrobiota be restored? Curr. Pharm. Des. 22, 6107-6121 (2016).
22. Hersoug, L. G., Moller, P. & Loft, S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes. Rev. 17, 297-312 (2016).
23. Dworkin, J. The medium is the message: interspecies and interkingdom signaling by peptidoglycan and related bacterial glycans. Annu. Rev. Microbiol. 68, 137-154 (2014).
24. Pimentel, M., Mathur, R. & Chang, C. Gas and the microbiome. Curr. Gastroenterol. Rep. 15, 356 (2013).
25. Macfabe, D. Autism: metabolism, mitochondria, and the microbiome. Glob. Adv. Health Med. 2, 52-66 (2013).
26. Macfabe, D. F. Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb. Ecol. Health Dis. 23 (2012). http://dx.doi.org/10.3402/mehd.v23i0.19260.
27. Al-Lahham, S. H., Peppelenbosch, M. P., Roelofsen, H., Vonk, R. J. & Venema, K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim. Biophys. Acta 1801, 1175-1183 (2010).
28. den Besten, G. et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325-2340 (2013).
29. Nakao, S., Moriya, Y., Furuyama, S., Niederman, R. & Sugiya, H. Propionic acid stimulates superoxide generation in human neutrophils. Cell. Biol. Int. 22, 331-337 (1998).
30. Han, J. H. et al. The effects of propionate and valerate on insulin responsiveness for glucose uptake in 3T3-L1 adipocytes and C2C12 myotubes via G protein-coupled receptor 41. PLoS. ONE 9, e95268 (2014).
31. Rorig, B., Klausa, G. & Sutor, B. Intracellular acidification reduced gap junction coupling between immature rat neocortical pyramidal neurones. J. Physiol. 490, 31-49 (1996).
32. Nguyen, N. H. et al. Propionate increases neuronal histone acetylation, but is metabolized oxidatively by glia. Relevance for propionic acidemia. J. Neurochem. 101, 806-814 (2007).
33. Nankova, B. B., Agarwal, R., MacFabe, D. F. & La Gamma, E. F. Enteric bacterial metabolites propionic and butyric acid modulate gene expression, including CREB-dependent catecholaminergic neurotransmission, in PC12 cells-possible relevance to autism spectrum disorders. PLoS. ONE 9, e103740 (2014).
34. Le Poul, E. et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278, 25481-25489 (2003).
35. DeCastro, M. et al. Short chain fatty acids regulate tyrosine hydroxylase gene expression through a cAMP-dependent signaling pathway. Brain Res. 142, 28-38 (2005).
36. Frye, R. E., Rose, S., Slattery, J. & MacFabe, D. F. Gastrointestinal dysfunction in autism spectrum disorder: the role of the mitochondria and the enteric microbiome. Microb. Ecol. Health Dis. 26, 27458 (2015).
37. Frye, R. E., Melnyk, S. & Macfabe, D. F. Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. Transl. Psychiatry 3, e220 (2013).
38. Al-Lahham, S. et al. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur. J. Clin. Invest. 42, 357-364 (2012).
39. Levison, M. E. Effect of colon flora and short-chain fatty acids on growth in vitro of Pseudomonas aeruginsoa and Enterobacteriaceae. Infect. Immun. 8, 30-35 (1973).
40. Donohoe, D. R. et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell. Metab. 13, 517-526 (2011).
41. Rane, P. et al. The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology 62, 2409-2412 (2012).
42. Stilling, R. M. et al. The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis? Neurochem. Int. 99, 110-132 (2016).
43. Brown, C. T. et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS. ONE 6, e25792 (2011).
44. Patterson, E. et al. Streptozotocin-induced type-1-diabetes disease onset in Sprague-Dawley rats is associated with an altered intestinal microbiota composition and decreased diversity. Microbiology 161, 182-193 (2015).
45. Butchbach, M. E. et al. Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Exp. Neurol. 279, 13-26 (2016).
46. Stefanikova, A., Klikova, K., Hatok, J. & Racay, P. ABT-737 accelerates butyrateinduced death of HL-60 cells. Involvement of mitochondrial apoptosis pathway. Gen. Physiol. Biophys. 32, 505-516 (2013).
47. Kurita-Ochiai, T. & Ochiai, K. Butyric acid induces apoptosis via oxidative stress in Jurkat T-cells. J. Dent. Res. 89, 689-694 (2010).
48. Tailor, D., Hahm, E. R., Kale, R. K., Singh, S. V. & Singh, R. P. Sodium butyrate induces DRP1-mediated mitochondrial fusion and apoptosis in human colorectal cancer cells. Mitochondrion 16, 55-64 (2014).
49. Wang, L., Luo, H. S. & Xia, H. Sodium butyrate induces human colon carcinoma HT-29 cell apoptosis through a mitochondrial pathway. J. Int. Med. Res. 37, 803-811 (2009).
50. Wang, Y. et al. Sodium butyrate-induced apoptosis and ultrastructural changes in MCF-7 breast cancer cells. Ultrastruct. Pathol. 40, 200-204 (2016).
51. Rodrigues, M. F., Carvalho, E., Pezzuto, P., Rumjanek, F. D. & Amoedo, N. D. Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin A on the energy metabolism of breast cancer cells. J. Cell. Biochem. 116, 797-808 (2015).
52. Natoni, F., Diolordi, L., Santoni, C. & Gilardini Montani, M. S. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim. Biophys. Acta 1745, 318-329 (2005).
53. Frye, R. E. & Rossignol, D. A. Identification and treatment of pathophysiological comorbidities of autism spectrum disorder to achieve optimal outcomes. Clin. Med. Insights Pediatr. 10, 43-56 (2016).
54. Rossignol, D. A. & Frye, R. E. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol. Psychiatry 17, 389-401 (2012).
55. Rossignol, D. A. & Frye, R. E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol. Psychiatry 17, 290-314 (2012).
56. Frye, R. E. Biomarker of abnormal energy metabolism in children with autism spectrum disorder. North Am. J. Med. Sci. 5, 141-147 (2012).
57. Parikh, S. et al. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet. Med. 19, 1-18 (2017).
58. Williams, B. L. et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS. ONE 6, e24585 (2011).
59. Finegold, S. M. et al. Gastrointestinal microflora studies in late-onset autism. Clin. Infect. Dis. 35, S6-S16 (2002).
60. MacFabe, D. F. Enteric short-chain fatty acids: microbial messengers of metabolism, mitochondria, and mind: implications in autism spectrum disorders. Microb. Ecol. Health Dis. 26, 28177 (2015).
61. Foley, K. A., MacFabe, D. F., Kavaliers, M. & Ossenkopp, K. P. Sexually dimorphic effects of prenatal exposure to lipopolysaccharide, and prenatal and postnatal exposure to propionic acid, on acoustic startle response and prepulse inhibition in adolescent rats: relevance to autism spectrum disorders. Behav. Brain Res. 278, 244-256 (2015).
62. Foley, K. A., MacFabe, D. F., Vaz, A., Ossenkopp, K. P. & Kavaliers, M. Sexually dimorphic effects of prenatal exposure to propionic acid and lipopolysaccharide on social behavior in neonatal, adolescent, and adult rats: implications for autism spectrum disorders. Int. J. Dev. Neurosci. 39, 68-78 (2014).
63. Foley, K. A., Ossenkopp, K. P., Kavaliers, M. & Macfabe, D. F. Pre- and neonatal exposure to lipopolysaccharide or the enteric metabolite, propionic acid, alters development and behavior in adolescent rats in a sexually dimorphic manner. PLoS. ONE 9, e87072 (2014).
64. Frye, R. E. Biomarkers of Abnormal Energy Metabolism in Children with Autism Spectrum Disorder. North Am. J. Med. Sci. 5, 141-147 (2012).
65. Frye, R. E. et al. Modulation of mitochondrial function by the microbiome metabolite propionic acid in autism and control cell lines. Transl. Psychiatry 6, e927 (2016).
66. Takuma, K. et al. Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism. Pharmacol. Biochem. Behav. 126, 43-49 (2014).
67. Kratsman, N., Getselter, D. & Elliott, E. Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model. Neuropharmacology 102, 136-145 (2016).
68. Kim, J. W. et al. Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism. PLoS. ONE 9, e104927 (2014).
69. Hong, J. et al. Butyrate alleviates high fat diet-induced obesity through activation of adiponectin-mediated pathway and stimulation of mitochondrial function in the skeletal muscle of mice. Oncotarget 7, 56071-56082 (2016).
70. Henagan, T. M. et al. Sodium butyrate epigenetically modulates high-fat dietinduced skeletal muscle mitochondrial adaptation, obesity and insulin resistance through nucleosome positioning. Br. J. Pharmacol. 172, 2782-2798 (2015).
71. Gao, Z. et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509-1517 (2009).
72. Sun, J. et al. Antidepressant-like effects of sodium butyrate and its possible mechanisms of action in mice exposed to chronic unpredictable mild stress. Neurosci. Lett. 618, 159-166 (2016).
73. Ferrante, R. J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427 (2003).
74. Govindarajan, N., Agis-Balboa, R. C., Walter, J., Sananbenesi, F. & Fischer, A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimer's Dis. 26, 187-197 (2011).
75. Sharma, B. & Singh, N. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology 215, 677-687 (2011).
76. Li, H. et al. Sodium butyrate exerts neuroprotective effects by restoring the blood-brain barrier in traumatic brain injury mice. Brain Res. 1642, 70-78 (2016).
77. Chang, J. G. et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. USA 98, 9808-9813 (2001).
78. Nafday, S. M. et al. Short-chain fatty acids induce colonic mucosal injury in rats with various postnatal ages. Pediatr. Res. 57, 201-204 (2005).
79. Rose, S. et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl. Psychiatry 2, e134 (2012).
80. Rose, S. et al. Oxidative stress induces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines in a well-matched case control cohort. PLoS. ONE 9, e85436 (2014).
81. Rose, S. et al. Mitochondrial and redox abnormalities in autism lymphoblastoid cells: a sibling control study. FASEB J. 31, 904-909 (2017).
82. Rose, S., Wynne, R., Frye, R. E., Melnyk, S. & James, S. J. Increased susceptibility to ethylmercury-induced mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines. J. Toxicol. 2015, 573701 (2015).
83. Rose, S. et al. Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines. Transl. Psychiatry 4, e377 (2014).
84. Frye, R. E. et al. Oxidative stress challenge uncovers trichloroacetaldehyde hydrate-induced mitoplasticity in autistic and control lymphoblastoid cell lines. Sci. Rep. 7, 4478 (2017).
85. Pellizzaro, C., Coradini, D. & Daidone, M. G. Modulation of angiogenesisrelated proteins synthesis by sodium butyrate in colon cancer cell line HT29. Carcinogenesis 23, 735-740 (2002).
86. Coradini, D., Pellizzaro, C., Marimpietri, D., Abolafio, G. & Daidone, M. G. Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. Cell. Prolif. 33, 139-146 (2000).
87. Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P. & Macfarlane, G. T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221-1227 (1987).
88. Karuri, A. R., Dobrowsky, E. & Tannock, I. F. Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment. Br. J. Cancer 68, 1080-1087 (1993).
89. Frye, R. E. et al. Objective phonological and subjective perceptual characteristics of syllables modulate spatiotemporal patterns of superior temporal gyrus activity. Neuroimage 40, 1888-1901 (2008).
90. Cueno, M. E. & Ochiai, K. Re-discovering periodontal butyric acid: New insights on an old metabolite. Microb. Pathog. 94, 48-53 (2016).
91. Jose, C., Melser, S., Benard, G. & Rossignol, R. Mitoplasticity: adaptation biology of the mitochondrion to the cellular redox state in physiology and carcinogenesis. Antioxid. Redox Signal. 18, 808-849 (2013).
92. Jiang, Y., Chen, J., Tong, J. & Chen, T. Trichloroethylene-induced gene expression and DNA methylation changes in B6C3F1 mouse liver. PLoS. ONE 9, e116179 (2014).
93. Kang, C. & Li, Ji. L. Role of PGC-1alpha signaling in skeletal muscle health and disease. Ann. NY Acad. Sci. 1271, 110-117 (2012).
94. Li, L. X., Skorpen, F., Egeberg, K., Jorgensen, I. H. & Grill, V. Uncoupling protein-2 participates in cellular defense against oxidative stress in clonal beta-cells. Biochem. Biophys. Res. Commun. 282, 273-277 (2001).
95. Giardina, T. M., Steer, J. H., Lo, S. Z. & Joyce, D. A. Uncoupling protein-2 accumulates rapidly in the inner mitochondrial membrane during mitochondrial reactive oxygen stress in macrophages. Biochim. Biophys. Acta 1777, 118-129 (2008).
96. Davis, L. M., Rho, J. M. & Sullivan, P. G. UCP-mediated free fatty acid uncoupling of isolated cortical mitochondria from fasted animals: correlations to dietary modulations. Epilepsia 49, 117-119 (2008).
97. Lee, J. S. & Lee, G. M. Effect of sodium butyrate on autophagy and apoptosis in Chinese hamster ovary cells. Biotechnol. Prog. 28, 349-357 (2012).
98. Ren, X., Dwivedi, Y., Mondal, A. C. & Pandey, G. N. Cyclic-AMP response element binding protein (CREB) in the neutrophils of depressed patients. Psychiatry Res. 185, 108-112 (2011).
99. Platenik, J. et al. GSK3beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 50, 83-93 (2014).
100. Cunningham, M. W. & Cox, C. J. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta Physiol. 216, 90-100 (2016).
101. De Angelis, M. et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS. ONE 8, e76993 (2013).
102. Kesli, R., Gokcen, C., Bulug, U. & Terzi, Y. Investigation of the relation between anaerobic bacteria genus clostridium and late-onset autism etiology in children. J. Immunoass. Immunochem. 35, 101-109 (2014).
103. Finegold, S. M. Therapy and epidemiology of autism-clostridial spores as key elements. Med. Hypotheses 70, 508-511 (2008).
104. Parracho, H. M., Bingham, M. O., Gibson, G. R. & McCartney, A. L. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J. Med. Microbiol. 54, 987-991 (2005).
105. Song, Y., Liu, C. & Finegold, S. M. Real-time PCR quantitation of clostridia in feces of autistic children. Appl. Environ. Microbiol. 70, 6459-6465 (2004).
106. Finegold, S. M., Downes, J. & Summanen, P. H. Microbiology of regressive autism. Anaerobe 18, 260-262 (2012).
107. Sandler, R. H. et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J. Child. Neurol. 15, 429-435 (2000).
108. Whiteley, P. et al. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr. Neurosci. 13, 87-100 (2010).
109. Thomas, R. H. et al. Altered brain phospholipid and acylcarnitine profiles in propionic acid infused rodents: further development of a potential model of autism spectrum disorders. J. Neurochem. 113, 515-529 (2010).
110. Thomas, R. H. et al. The enteric bacterial metabolite propionic acid alters brain and plasma phospholipid molecular species: further development of a rodent model of autism spectrum disorders. J. Neuroinflammation 9, 153 (2012).
111. Conn, A. R., Fell, D. I. & Steele, R. D. Characterization of alpha-keto acid transport across blood-brain barrier in rats. Am. J. Physiol. 245, E253-E260 (1983).